FDA ap­proves oral for­mu­la­tion of old ALS drug, giv­ing pa­tients new treat­ment op­tion in sore­ly need­ed field

Much of the ALS drug news in re­cent months has fo­cused on Amy­lyx Phar­ma­ceu­ti­cals and its ex­per­i­men­tal pro­gram re­viewed by an FDA ad­vi­so­ry com­mit­tee in March. But on Thurs­day, the FDA green­light­ed a new way to take an al­ready-ap­proved ALS drug that flew un­der the radar.

US reg­u­la­tors OK’ed an oral for­mu­la­tion of Rad­i­ca­va, first ap­proved to treat ALS back in 2017 as a se­ries of IV in­fu­sions, to treat adults with ALS, the agency an­nounced Thurs­day af­ter­noon. The de­ci­sion gives pa­tients an­oth­er op­tion for a uni­ver­sal­ly fa­tal dis­ease with on­ly one oth­er ap­proved drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER